Avillion LLP gets initial funding from Abingworth, Clarus Ventures
Avillion LLP, which focuses on clinical co-development of therapeutics, has said it has secured initial funding from Abingworth LLP and Clarus Ventures. UK-based Avillion is partnering with pharmaceutical and biotechnology companies to co-develop and finance late stage therapeutics.
The company will use its clinical development and regulatory expertise to get the global approvals for a broad range of drugs and biologics.
Lewis Cameron, CEO of Avillion said, “Avillion offers pharma and biotech companies compelling option to collaborate late stage drug approval projects globally. “ Mr. Cameron also said, “We have an experienced team focused on global drug development and approval, with the capability to optimize CRO management.”
The management team is led by Lewis Cameron who has held senior positions in CRO companies including Chiltern International, Clearstone and LabCorp, Dr Allison Jeynes-Ellis has more than 20 years’ experience running clinical trials for pharmaceutical companies like BMS and Wyeth.
It has also been extensively involved in health technology appraisals across various countries. Graham Higson (VP, Regulatory) has three decades of regulatory experience, including 5 years as the global head of regulatory affairs at AstraZeneca. Abingworth is a global investment group dedicated mainly to the life sciences and healthcare sector.
The company invests at all stages of development including early and late-stage venture financing, growth equity and public companies.
Clarus Ventures is a life sciences venture capital company founded by a team of accomplished investment and operating professionals.